211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
Conditions
- Acute Lymphoblastic Leukemia in Remission
- Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
- Acute Myeloid Leukemia in Remission
- Chronic Myelomonocytic Leukemia
- Myelodysplastic Syndrome With Excess Blasts
- Recurrent Acute Lymphoblastic Leukemia
- Recurrent Acute Myeloid Leukemia
- Refractory Acute Lymphoblastic Leukemia
- Refractory Acute Myeloid Leukemia
- Recurrent Mixed Phenotype Acute Leukemia
- Refractory Mixed Phenotype Acute Leukemia
- Hematopoietic and Lymphoid Cell Neoplasm
Interventions
- BIOLOGICAL: Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10
- DRUG: Cyclophosphamide
- RADIATION: Total-Body Irradiation
- PROCEDURE: Peripheral Blood Stem Cell Transplantation
- PROCEDURE: Bone Marrow Transplantation
- DRUG: Mycophenolate Mofetil
- BIOLOGICAL: Recombinant Granulocyte Colony-Stimulating Factor
- DRUG: Fludarabine Phosphate
- DRUG: Tacrolimus
- PROCEDURE: Bone Marrow Aspiration and Biopsy
- PROCEDURE: Biospecimen Collection
Sponsor
Fred Hutchinson Cancer Center
Collaborators